New hope for Still's disease: experimental drug enters Mid-Stage trial
NCT ID NCT07203001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called MAS825 for people with Still's disease, a rare inflammatory condition causing fever, rash, and joint pain. About 20 children and adults with active disease will receive the drug to see if it safely controls symptoms. The goal is to improve daily life by reducing inflammation and flares.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STILL´S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Cincinnati Childrens Hospital
RECRUITINGCincinnati, Ohio, 45229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Legacy Emanuel Research Hosp Portland
RECRUITINGPortland, Oregon, 97232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Novartis Investigative Site
WITHDRAWNMontreal, Quebec, H3T 1C5, Canada
-
Novartis Investigative Site
WITHDRAWNMontreal, Quebec, H4A 3J1, Canada
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGBron, 69677, France
-
Novartis Investigative Site
RECRUITINGLe Kremlin-Bicêtre, 94275, France
-
Novartis Investigative Site
RECRUITINGLille, 59037, France
-
Novartis Investigative Site
RECRUITINGParis, 75015, France
-
Novartis Investigative Site
RECRUITINGParis, 75970, France
-
Novartis Investigative Site
RECRUITINGSankt Augustin, North Rhine-Westphalia, 53757, Germany
-
Novartis Investigative Site
RECRUITINGHeidelberg, 69120, Germany
-
Novartis Investigative Site
RECRUITINGMünster, 48149, Germany
-
Novartis Investigative Site
RECRUITINGFlorence, FI, 50139, Italy
-
Novartis Investigative Site
RECRUITINGGenova, GE, 16147, Italy
-
Novartis Investigative Site
RECRUITINGRoma, RM, 00165, Italy
-
Novartis Investigative Site
RECRUITINGUtrecht, 3584 CX, Netherlands
-
Novartis Investigative Site
RECRUITINGEsplugues, Barcelona, 08950, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28046, Spain
-
Novartis Investigative Site
RECRUITINGValencia, 46026, Spain
-
Novartis Investigative Site
RECRUITINGIstanbul, Fatih, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGAnkara, Sihhiye-Altindag, 06230, Turkey (Türkiye)